4-(4-碘苯基)四氢-1(2H)-吡嗪羧酸叔丁酯 | 151978-66-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-(4-碘苯基)四氢-1(2H)-吡嗪羧酸叔丁酯
• 英文名称: tert-butyl 4-(4-iodophenyl)piperazine-1-carboxylate
• CAS: 151978-66-4
• 化学式: C₁₅H₂₁IN₂O₂
• mdl: MFCD06200864
• 分子量: 388.248
• InChiKey: ZOWJTZMYSLZILG-UHFFFAOYSA-N

物化性质

• 熔点：
  150 °C
• 沸点：
  439.5±40.0 °C(Predicted)
• 密度：
  1.481±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.533
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319

SDS

Name:	tert-Butyl 4-(4-iodophenyl)tetrahydro-1(2H)-pyrazinecarboxylate Material Safety Data Sheet
Synonym:	None Known
CAS:	151978-66-4

Section 1 - Chemical Product MSDS Name:tert-Butyl 4-(4-iodophenyl)tetrahydro-1(2H)-pyrazinecarboxylate Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
151978-66-4	tert-Butyl 4-(4-iodophenyl)tetrahydro-	97+	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 151978-66-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 149-150 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C15H21IN2O2
Molecular Weight: 388.0637

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Oxidizing agents, acids.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide, hydrogen iodide, iodine.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 151978-66-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
tert-Butyl 4-(4-iodophenyl)tetrahydro-1(2H)-pyrazinecarboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 24/25 Avoid contact with skin and eyes.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 151978-66-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 151978-66-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 151978-66-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(4-碘苯基)四氢-1(2H)-吡嗪羧酸叔丁酯 在 四(三苯基膦)钯 、 草酰氯 、 四丁基氟化铵 、 三乙酰氧基硼氢化钠 、 sodium carbonate 、 potassium carbonate 、 二甲基亚砜 、 三氟乙酸 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 乙醇 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 70.08h， 生成 N6-(2-(4-(3′-methoxybiphenyl-4-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine
  参考文献：
  名称：

  神经保护性抗帕金森病 (-)-N6-(2-(4-(Biphenyl-4-yl)piperazin-1-yl)-乙基)-N6-丙基-4,5,6,7-四氢苯并[ d]thiazole-2,6-diamine (D-264)：致力于提高母体分子的体内功效

  摘要：

  在我们开发用于治疗帕金森病 (PD) 的多功能多巴胺 D 2 /D 3激动剂药物的总体目标中，我们之前合成了有效的 D 3偏好激动剂 D-264 ( 1a )，其在两种 PD 动物模型中表现出神经保护特性. 为了提高1a 的体内功效，进行了构效关系研究。竞争性结合和 [ 35 S]GTPγS 功能测定将化合物 (-)- 9b鉴定为具有优先 D 3激动剂活性的先导分子之一(EC 50 (GTPγS)；D 3 = 0.10 nM；D 2 /D 3(EC 50 )：159)。化合物 (-)- 9b和 (-)- 8b在两种 PD 动物模型、利血平化和 6-羟基多巴胺 (OHDA) 诱导的单侧损伤大鼠中表现出高体内活性。另一方面，除非将化合物溶解在 5-10% 的 β-羟丙基环糊精溶液中，否则1a在这些模型中没有表现出任何体内活性。先导化合物表现出明显的自由基清除活性。多巴胺能 MN9D 细胞的体外实验表明1a和

  DOI：

  10.1021/jm401883v
• 作为产物：
  描述：

  1-Boc-4-(4-溴苯基)哌嗪 在 copper(l) iodide 、 sodium iodide 、 N,N'-二甲基乙二胺 作用下， 以 甲苯 为溶剂， 反应 72.0h， 生成 4-(4-碘苯基)四氢-1(2H)-吡嗪羧酸叔丁酯
  参考文献：
  名称：

  WO2007/97937

  摘要：

  公开号：

文献信息

• [EN] KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME<br/>[FR] INHIBITEURS DE KINASES ET PROCÉDÉ DE TRAITEMENT DU CANCER AVEC CEUX-CI
  申请人：UNIV HEALTH NETWORK

  公开号：WO2010115279A1

  公开（公告）日：2010-10-14

  The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

  这项发明涉及一种由以下结构式表示的化合物及其药用可接受的盐：由该结构式表示的化合物是激酶抑制剂，因此在此披露用于治疗癌症。结构式中变量的定义在此提供。
• [EN] GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS<br/>[FR] PYRIDINES/PYRIMIDINES AMINO SPIROCYCLIQUES ET DISUBSTITUÉES PAR GEM EN TANT QU'INHIBITEURS DE CYCLE CELLULAIRE
  申请人：AMGEN INC

  公开号：WO2009126584A1

  公开（公告）日：2009-10-15

  Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-mediated disorders, such as cancer. The subject compounds are gem-disubstituted or spirocyclic pyridine, pyrimidine and triazine derivatives.

  提供了一些化合物、药物组合物和方法，这些化合物、药物组合物和方法可用于治疗CDK4介导的疾病，如癌症。所述化合物是 gem-二取代或螺环的吡啶、嘧啶和三嗪衍生物。
• Catalytic Aldehyde and Alcohol Arylation Reactions Facilitated by a 1,5-Diaza-3,7-diphosphacyclooctane Ligand
  作者：Eric S. Isbrandt、Amrah Nasim、Karen Zhao、Stephen G. Newman

  DOI：10.1021/jacs.1c05661

  日期：2021.9.15

  interrupted carbonyl-Heck type mechanism is proposed to be operative, with a key 1,2-insertion step forging the new C–C bond and forming a nickel alkoxide that may be turned over by an alcohol reductant. The same catalyst was also found to enable synthesis of ketone products from either aldehydes or alcohols, demonstrating control over the oxidation state of both the starting materials and products.

  我们报告了一种通过芳基碘化物偶联获得仲醇的催化方法。醛或醇都可以用作反应伙伴，分别使转化还原或氧化还原中性。该反应由 Ni 催化剂和 1,5-二氮杂-3,7-二磷酸环辛烷介导。这个 P 2 N 2以前在交叉偶联和相关反应中未被识别的配体被发现可以避免有害的芳基卤化物还原途径，而这些途径主要由更传统的膦和 NHCs 支配。提出了一种间断的羰基-Heck 型机制，其中一个关键的 1,2-插入步骤形成新的 C-C 键并形成可能被醇还原剂翻转的镍醇盐。还发现相同的催化剂能够从醛或醇合成酮产物，证明对起始材料和产物的氧化态的控制。
• Diastereo- and Enantioselective Ruthenium-Catalyzed C-C Coupling of 1-Arylpropynes and Alcohols: Alkynes as Chiral Allylmetal Precursors in Carbonyl <i>anti</i>-(α-Aryl)allylation
  作者：Ming Xiang、Ankan Ghosh、Michael J. Krische

  DOI：10.1021/jacs.0c12242

  日期：2021.2.24

  pronucleophiles in ruthenium-JOSIPHOS-catalyzed anti-diastereo- and enantioselective aldehyde (α-aryl)allylations with primary aliphatic or benzylic alcohol proelectrophiles. This method enables convergent construction of homoallylic sec-phenethyl alcohols bearing tertiary benzylic stereocenters. Both steric and electronic features of aryl sulfonic acid additives were shown to contribute to the efficiency with

  高度易处理的 1-aryl-1-propynes，很容易通过 Sonogashira 偶联获得，在钌-JOSIPHOS 催化的抗非对映和对映选择性醛（α-芳基）烯丙基化与伯脂肪族或苄醇亲电子试剂中用作手性烯丙基金属亲核试剂。该方法能够收敛构建同烯丙基sec-带有叔苄基立体中心的苯乙醇。芳基磺酸添加剂的空间和电子特性均被证明有助于形成更具选择性和生产性的碘化物结合的钌催化剂的效率。正如同位素标记研究所证实的那样，双重催化过程是有效的，其中炔烃到丙二烯异构化之后是丙二烯-羰基通过氢自动转移进行还原偶联。观察到从这两个离散的催化事件中产生的氢化钌的交叉。该方法的实用性通过将选定的反应产物转化为相应的苯乙胺和新木脂素天然产物 (-)-山楂 A-D 的首次全合成来说明。
• [EN] BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS BIFONCTIONNELS POUR LE TRAITEMENT DU CANCER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2021083949A1

  公开（公告）日：2021-05-06

  The invention provides bifunctional compounds of formula (I) or a pharmaceutically acceptable salt thereof. Formula (I). The compounds cause the degradation of SMARCA2 via the targeted ubiquination of SMARCA2 protein and subsequent proteasomal degradation and are thus useful for the treatment of cancer. The targeting ligand is of formula (TL).

  该发明提供了式（I）的双功能化合物或其药用可接受的盐。式（I）。这些化合物通过靶向泛素化SMARCA2蛋白并随后的蛋白酶体降解来导致SMARCA2的降解，因此对于癌症的治疗是有用的。靶向配体的化学式为（TL）。